Skip to main content

Medical disclaimer: This site is educational and does not provide individualized medical advice. Always consult a licensed clinician about your situation.

Evidence comparison

Incretin medicine vs. teriparatide: evidence fields

These medicines have different approved indications and evidence bases; this comparison does not recommend switching or combining therapies.

FieldSemaglutideTeriparatide
Primary approved useType 2 diabetes / chronic weight management.Osteoporosis in postmenopausal women and men at high fracture risk.
Peptide relationshipGLP-1 analogPTH fragment
Key women's evidenceObesity/diabetes trials enrolled majorities of women; sex subgroup analyses are reported but limited.Pivotal fracture trial in 1,637 postmenopausal women with osteoporosis.

Sources

Primary records

Author

Ian Gauntt

RN, BSN — 10 years as a critical care nurse

Medical reviewer

Medical Reviewer (Pending Assignment)

Medical review pending assignment by a licensed clinician.

Last reviewed 2026-08-01Next review 2026-11-01

Medical disclaimer: Her Health Peptides publishes educational, source-linked summaries. We do not provide individualized medical advice, diagnosis, or treatment recommendations. Always talk with a licensed clinician about your specific situation, especially if you are pregnant, breastfeeding, planning pregnancy, or taking other medicines.

The Women's Evidence Brief — one audit, one update, one evidence lesson each week.

Join the list